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Abstract
Background: Evidence of quality of life implications of asthma attacks are limited, particularly when measured on
a utility scale, which enables calculating Quality-Adjusted Life-Years (QALYs) and comparisons with other health
conditions and services. Therefore, this study sought to estimate the utility loss associated with an asthma-related
crisis event (accident and emergency (A&E) attendance or hospital admission).
Methods: Participants were recruited in a cohort study from A&E and hospital admissions at three UK hospitals.
They completed the EuroQol-5 Dimensions 5-Level (EQ-5D-5 L), Asthma Quality of Life Questionnaire (AQLQ), Time
trade-off (TTO), and peak flow and symptom diary over 8 weeks, where three different methods (EQ-5D-5 L, AQLQ,
and TTO), were used to estimate utilities. The mean difference between two time points were estimated using the
Wilcoxon signed rank test.
Results: From baseline to week 8, mean increases (95% CI) were estimated to be 0.086 (0.019–0.153), 0.154
(0.112–0.196) and 0.132 (0.063–0.201) for EQ-5D-5 L, AQL-5D (preference-based measure derived from AQLQ), and
TTO respectively over 8 weeks (p < 0.01).
Conclusion: Asthma crisis events are estimated to be associated with a mean utility loss of between 0.086 and
0.132. The utility decrement can be used to assign values to asthma-related crisis events, which can enhance
economic evaluations.
Trial registration: NCT02771678. Registered 13 May 2016.
Keywords: Asthma, Crisis event, Quality of life, Utility estimations, UK
Introduction
Asthma has a prevalence of over 300 million people
worldwide, and it can be a severe and life threatening
condition [1]. Each week in England and Wales, there
are 1400 asthma patients hospitalized, and direct costs
are estimated to amount to over £1 billion [2, 3]. The
onset of asthma symptoms can develop gradually or
suddenly lead to an attack, leading to impaired quality of
life [4].
Generic and disease-specific patient reported outcome
measures (PROMs) can be used to measure an individ-
ual’s health state. Many asthma-related studies have used
PROMs [4–6], however, they mostly measure PROMs at
specific time points (e.g. baseline and 6months) and (as
they have no information as to what happens in be-
tween) assume linear interpolation (a gradual straight
line change) between such points [7]. Others have ar-
gued, however, that such methods may not capture the
loss in quality of life associated with particular health
events [8–10]. Asthma attacks are unpredictable, and if
they occur between specific time points of measurement
(e.g. baseline and 6months), the loss associated with an
event may not be captured and consequently, overall
quality of life could potentially be overestimated.
Conversely, if a follow up time point occurred during an
asthma-related event, then using the linear interpolation
method could result in underestimating overall quality
of life. Therefore, with the above method, there is a
potential for the utility estimates (a scale on which 0 is
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equivalent to death and 1 is full health), QALY values,
and cost-effectiveness to be inaccurate, with the possibil-
ity that treatments could be recommended for provision
when they are not in fact cost-effective, or not recom-
mended when they are in fact cost-effective.
In light of the above, the objective of this study is to
estimate the loss in health-related quality of life and en-
able QALY values to be estimated via an alternative
method associated with an asthma crisis event (A&E at-
tendance or hospital admission). This will enable studies
that capture outcomes in terms of A&E attendances or
hospital admissions to also convert their outcomes, akin
to mapping [11, 12], into QALY estimates. This is in line
with NICE methods recommendations [13, 14], and it
will enable recommendations about whether NHS
provision of particular interventions constitutes value
for money to be more readily made.
Methods
Study design
The ESQUARE study was an 8 week prospective, obser-
vational cohort study. The target sample size was
between 100 and 200 participants, with consideration of
the retention rate [15] and previous literature [16–18].
Originally the aim was to recruit 100 participants
informed by the literature. However, due to the large un-
foreseen number of participants who did not complete
the study due to withdrawals or loss to follow up, the
sample size was increased to 200 participants to aid with
retaining participants who would complete the whole
study.
Participant recruitment
Participants were screened and recruited in the UK from
the Norfolk and Norwich University Hospital in Nor-
wich, the Queen Elizabeth Hospital in Birmingham and
the Aberdeen Royal Infirmary in Aberdeen. Approval
was granted by the Cambridge South Research Ethics
Committee and recruitment took place between May
2016 and May 2017. Participants were eligible if they
had an asthma-related crisis event and a diagnosis of
asthma alone, or asthma with Chronic Obstructive
Pulmonary Disease (COPD) or asthma with a respiratory
infection. They also had to be ≥18 years old, able to
speak English and give informed consent. Participants
were excluded if they had life threatening hypoxaemia
(unable to speak in short sentences), were unable to
complete questionnaires unaided, or if they had already
participated in the study.
Study procedures
The investigators and respiratory staff identified and
consented participants from the daily hospital triage.
After obtaining consent, participants were asked to
complete baseline questionnaires in the presence of a
researcher (demographics questionnaire, EQ-5D-5 L
[19], AQLQ [20], and TTO [21]), and given two packs of
questionnaires to complete for the 8 weeks. The first
pack included the EQ-5D-5 L, AQLQ and a peak flow
and symptom diary (see below), to be completed for the
first four weeks. The second pack (posted at week 3 of
the study), contained the same aforementioned question-
naires, to be completed for the last four weeks.
Throughout the 8 week period the EQ-5D-5 L was
requested to be completed weekly, the AQLQ every 4
weeks, the TTO every 4 weeks and the peak flow and
symptom diary daily. Participants were also telephoned
or seen face to face (depending on locations and sched-
ules of routine hospital follow-ups) at weeks 3, 4, 6, and
8 to monitor progress and asked further questions
regarding adverse events, changes in asthma medica-
tions, comorbidities, smoking status and to complete the
TTO. Participants returned the completed question-
naires in freepost envelopes provided, and received £30
in vouchers to thank them for their time participating in
the study. (See Additional file 1).
Outcome measures
Table 1 shows the array of questionnaires and forms
requested at different time points of the study.
Table 1 Time and events during the study
Questionnaires/Forms Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8
Researcher with participant completion
Consent form X
Patient and GP details form X
Time Trade Off X X X
Participant completion
Demographics questionnaire X
EuroQol-5 Dimensions-5 Level Questionnaire X X X X X X X X X
Asthma Quality of Life Questionnaire X X X
Peak flow and symptoms diary Completion of this diary was requested every day from baseline through to week 8
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EuroQol-5 dimensions 5 levels (EQ-5D-5 L)
The EQ-5D is a widely used questionnaire and is recom-
mended by NICE for use in economic evaluation studies
[22], and the EQ-5D-5 L is currently undergoing re-
search for its suitability in technology appraisals [23].
The EQ-5D-5 L is a generic questionnaire composed of
5 dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression). Each dimension has
5 levels (no problems, slight problems, moderate
problems, severe problems, extreme problems/unable),
and describes the participants’ health on the day the
questionnaire is completed [24]. If all 5 questions are
answered, the responses are converted into a health
index score to generate a utility value on a scale of 0
(death) to 1 (full health) [25]. In addition, there is also a
Likert scale called the Visual Analogue Scale (VAS),
ranging from 0 (the worst health you can imagine) to
100 (the best health you can imagine), where the partici-
pant records a value which best describes their health.
Asthma quality of life questionnaire (AQLQ)
The AQLQ is a disease-specific questionnaire consisting
of 32 asthma-related questions, based on the partici-
pants’ last 2 weeks. There are 7 different response
choices for each question ranging from 1 (e.g. all of the
time) to 7 (e.g. none of the time) [20]. Additionally, re-
sponses to five questions around sleep, concern, breath,
pollution and activity were used from the AQLQ to de-
velop the preference based measure called the AQL-5D.
Associated utility values between 0 and 1 were derived
based on using the TTO from a random sample of the
UK population [26]. It is recommended in the literature
that disease-specific instruments should be used in
conjunction with generic HRQL instruments [22].
Therefore, both the EQ-5D-5 L and AQL-5D were used
together to inform this study, with the added benefit of
both questionnaires having five dimensional levels.
Time trade off (TTO)
In line with previous work, the TTO method used was
modified slightly [27]. The two options are typically the
condition of interest and full health. In this case, the two
options were current asthma health state and well
controlled asthma. The latter option was chosen in order
to enable one to specifically estimate the loss in quality
of life associated with an asthma-related crisis event,
without having to adjust for any co-morbidities that may
be present. The TTO had an advantage over using the
quality of life questionnaires (e.g. EQ-5D-5 L), because it
was designed as such with a view to be able to identify
whether the participant has returned back to their
well-controlled asthma state, therefore reducing the
possibility of underestimating the loss in quality of life
associated with an asthma crisis event if they have still
not returned to a well-controlled state by week 8.
The chosen life expectancy for the TTO was that of
the general population [28], taking account of the
individuals’ age and sex, as if asthma is well controlled
then the individual should be able to live a normal life,
equivalent to a healthy person (dependent of other
comorbidities) [29].
The TTO was asked at baseline by a face to face
consultation, initially using a visual on a laptop to aid
the explanation of the TTO. The TTO follow-ups con-
ducted at week 4 and week 8 of the study were provided
either face to face at the participant’s routine hospital
appointment or over the telephone. The initial face to
face consultation at baseline was intended to help the
participants remember the visual displayed for their
telephone consultation. For this study, the iterative ques-
tioning of the TTO began at the mid-point of the partic-
ipant’s estimated remaining average life expectancy, with
incremental movements during the TTO process by 10%
of their estimated remaining average life expectancy
rounded to the nearest 10.
Peak expiratory flow (PEF) and symptoms diary
A diary was used to record participants’ PEF (recorded
morning and evening) and symptom severity in relation
to three questions from the Royal College of Physicians
(RCP) [30]. The three questions were as follows, where
the response options were no symptoms, slight, moder-
ate or severe symptoms:
1. Have you had difficulty sleeping because of your
asthma?
2. Have you had your usual asthma symptoms during
the day (cough, wheeze, breathlessness, chest
tightness)?
3. Has your asthma interfered with your usual activities
(e.g. housework, childcare, work, school etc.)?
Statistical analysis
Double data entry was conducted for 10% of the data
collected, where there was only 5 out of 1600 (0.31%)
data points that differed between both data sets, indicat-
ing that accuracy was high. Baseline and descriptive sta-
tistics were explored from available cases using STATA
(v.12) and Microsoft Excel (2016) software packages.
Mean changes and ranges of the utility values and scores
for each follow up time point were computed. As the
data followed a non-normal distribution, the Wilcoxon
signed-rank test at the 5% statistical level was conducted
for available case analysis. The QALY loss was also
estimated, for each of the EQ-5D-5 L, AQLQ-5D and
TTO, by taking account of the utility values and the
time points at which these questionnaires were asked.
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The predicted PEF was estimated using the mini-wright
online PEF calculator [31]. Response rates, floor and
ceiling effects, were also tabulated at different time
points of the study.
Results
Demographics
Across all three hospital sites, 223 participants were
screened for eligibility. Of these, 121 were recruited into
the study, with 42 (35%) lost to follow up (8 week scores
not completed) and 8 (7%) withdrawals (Fig. 1).
The mean age of participants was 50 years old, with
26.5% male and 95.8% white (Table 2).
At baseline, self-reported data from the demographics
questionnaire indicated that the most frequent route of
entry into hospital was by GP or nurse referral (42%), or
by ambulance (42%), and for 60% of participants, the
peak of their asthma event occurred before hospital.
Medical records reported that the average length of stay
was 5.0 days. The response rates for the EQ-5D-5 L,
TTO, AQLQ symptoms, emotional and environmental
scores showed evidence of ceiling effects (Table 3). The
TTO had the highest percentage of 18.8% for ceiling
effects, as 21 participants reported that they were not
willing to reduce their life expectancy in exchange for an
improvement in asthma control. The baseline response
rates ranged from 97.5 to 100.0%.
Utility and QALY loss
Table 4 shows the utility and score results at all the time
points. The preference based questionnaires (EQ-5D-5 L,
AQL-5D, and TTO) showed statistical significant differ-
ences (p < 0.01) between baseline and week 8 (Table 5).
Likewise, the PROMs observed between baseline and
Fig. 1 Recruitment flow diagram
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week 4, were also all statistically significant (p < 0.01).
(Table 6) However, for the PROM scores where the
comparison was between week 4 and week 8, only the
AQLQ overall score and AQL-5D were statistically
significantly different (p < 0.05) (see Additional file 2).
The estimated QALY loss over the first eight weeks for
an asthma-related crisis event for the EQ-5D-5 L,
AQL-5D and TTO is 0.007, 0.012 and 0.010 QALYs
respectively, with the assumption of linear interpolation
between baseline and week 8 for the available case
analysis.
Peak flow and asthma symptoms
The mean difference between week 8 and baseline was
64 L/min, which was a statistically significant difference
(p < 0.05). The mean best and predicted PEF were 377
and 490 respectively, indicating that participants PEF
had not returned to their best or predicted values by
week 8 (see Additional file 3).
On average, all participants who responded to the RCP
symptom question (N = 60) reported mild symptoms
approximately one week after consent into the study
(see Additional file 4). However, 6.6% of responding par-
ticipants reported another asthma-related hospitalization
during the study and 28.9% reported changes to their
medications. New comorbidities and smoking status
arose within the 8 weeks for some participants, averaging
at 2.5 and 3.3% respectively.
Discussion
This study explored quality of life in people with acute
asthma who attended A&E or were admitted to hospital
with an asthma attack. The aim was to estimate the
associated utility/QALY loss for the aforementioned
patient population, to enable studies to use these estima-
tions, and aid their decision about the best value for
money for particular interventions. The mean differences
Table 2 Baseline characteristics
Demographics N = 121
Age (mean, years) 49.68
Height (mean, cm) 167.22
Weight (mean, kg) 85.54
Gender (%)
Male 26.45
Female 73.55
Ethnicity (%)
White 95.83
Mixed White and Black 0.83
White Other 3.33
Smoking Status (%)
Never 42.50
Non-Smoker 1.67
Smoker 15.00
Ex-Smoker 40.83
Highest Level of Education (%)
School 47.06
College 33.61
Degree 19.33
Employment status (%)
Full-time 27.50
Part-time 15.83
Retired 28.33
Stay at home parents 7.50
Student 3.33
Unemployed 17.50
Table 3 Baseline statistics for each quality of life questionnaire
Item N Mean SD Range Response rates Floor effects Ceiling effects
EQ-5D-5 L (utility) 120 0.635 0.274 −0.102 to 1.00 99.2% 0.00% 8.30%
VAS score 120 45.7 19.3 5.00 to 90.0 99.2% 0.00% 0.00%
AQLQ overall score 120 3.28 0.963 1.18 to 5.30 99.2% 0.00% 0.00%
AQLQ Symptoms score 121 2.81 1.06 0.00 to 5.50 100.0% 0.00% 2.50%
AQLQ Activity score 121 3.51 1.05 0.00 to 5.82 100.0% 0.00% 0.00%
AQLQ Emotional score 121 3.14 1.51 0.00 to 7.00 100.0% 0.00% 4.10%
AQLQ Environmental score 121 4.04 1.52 0.00 to 7.00 100.0% 0.00% 1.70%
AQL-5D (utility) 118 0.608 0.128 0.450 to 0.935 97.5% 0.00% 0.00%
TTO (utility) 112 0.626 0.277 0.100 to 1.00 100.0%a 0.00% 18.8%
aThe response rate is based on the denominator being 112 due to only the participants based at the Norfolk and Norwich University Hospital (NNUH) being asked
the TTO questions. All of the other response rates for the PROMS were based on the denominator being 121 as this was the total number recruited across all
hospital sites where each participant was asked to complete PROM questionnaires. Ranges for PROMs: EQ-5D-5 L (−0.281 to 1); EQ-5D VAS (0 to 100); AQLQ
(0 to 7); AQL-5D (0 to 1); TTO (0 to 1)
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between week 8 and baseline were 0.086, 0.154 and 0.132
for the EQ-5D-5 L, AQL-5D and TTO utilities respect-
ively. Assuming linear interpolation, their corresponding
QALY loss estimates over the first 8 weeks were 0.007,
0.012 and 0.010 QALYs respectively.
There are a number of strengths from this study. The
participants were recruited during one year from three
hospital sites, which enhanced the generalisability of the
collected data for the asthma population. Several
PROMs were used in this study to gain a more compre-
hensive perspective on quality of life in people with
acute asthma. A limitation is however, that the peak of
the asthma-related crisis event could have occurred
before A&E attendance or hospital admission, meaning
that the baseline score may not equate to the worst
point and the reported change scores therefore represent
an underestimate of the loss in quality of life associated
with an asthma crisis event. Secondly, since the partici-
pants had not yet returned to their normal PEF at week
8 of the study, the estimation in quality of life associated
with an asthma crisis event could have also been further
underestimated. Thirdly, participants were excluded if
they were unable to complete the questionnaires
unaided, which could have potentially excluded the ex-
tremely severe asthma participants, again meaning that
the estimated loss in utility could have been underesti-
mated. Fourthly, the retention rate was problematic and
the sample size was small, with a large proportion of
participants lost to follow up, despite phone call
reminders. The low retention rate could have been due
to the study length being too long [32], but may also be
related to the population in question e.g. asthmatics
have been shown to often be non-compliant with attend-
ing clinic appointments [33]. Finally, we should acknow-
ledge that though there is an argument for correcting
TTO scores for time preference [34], we have not done
so as this is not generally undertaken and there is no
one agreed correction factor [35].
An earlier four week study used the EQ-5D-3 L in
asthmatics, and estimated the mean utility loss associ-
ated with an asthma hospitalization as 0.20 [32], which
differs from our mean findings of 0.13. However, the
earlier study used the EQ-5D-3 L, [32], compared to this
study using the EQ-5D-5 L, and though the 5 level aims
to improve sensitivity [24] it has been shown that the 3
L version can lead to higher utility gains compared to
the EQ-5D-5 L [36]. Some of the difference observed
could have also occurred, as in the previous study
patients were not experiencing an asthma attack at the
point at which they were recruited into the study [32],
as recruitment was from outpatient clinics and primary
care. Accordingly, their score at the time of event was
compared to their pre-admission score, whereas our
comparison was the 8 week score. It may be that in our
study they had not recovered to their pre-admission
score by that point, meaning that our aforementioned
estimates may represent conservative estimates, as to the
loss in quality of life associated with an asthma crisis
event.
The ceiling effects for the TTO (anchor: well-con-
trolled asthma) were 18.8% at baseline, and increased to
51.7 and 51.3% at weeks 4 and 8 respectively (see Add-
itional files 5 and 6). Here participants report not being
willing to trade reductions in life expectancy in exchange
Table 5 Mean changes in utility and score values between baseline and week 8 (available case analysis)
Outcome measure N Baseline Mean ± SD 8 weeks Mean ± SD Mean difference (95% CI) P-value
EQ-5D-5 L (utility) 64 0.639 ± 0.267 0.725 ± 0.294 0.086 (0.153 to 0.019) 0.007**
VAS (score) 64 48.81 ± 18.58 67.88 ± 22.03 19.06 (25.69 to 12.44) 0.000**
AQLQ overall (score) 65 3.20 ± 0.955 4.48 ± 1.50 1.28 (1.60 to 0.963) 0.000**
AQL-5D (utility) 62 0.582 ± 0.120 0.736 ± 0.178 0.154 (0.196 to 0.112) 0.000**
TTO (utility) 80 0.655 ± 0.273 0.787 ± 0.295 0.132 (0.201 to 0.063) 0.000**
Wilcoxon signed-rank test
**p-value < 0.01 therefore statistically significant at the 1% level
Table 6 Mean change in utility and score values between baseline and week 4 (available case analysis)
Outcome measure N Baseline Mean ± SD 4 weeks Mean ± SD Mean difference (95% CI) P-value
EQ-5D-5 L (utility) 71 0.613 ± 0.275 0.740 ± 0.264 0.127 (0.193 to 0.061) 0.000**
VAS (score) 73 47.38 ± 20.08 65.95 ± 21.42 18.56 (23.40 to 13.72) 0.000**
AQLQ (score) 70 3.16 ± 0.980 4.09 ± 1.48 0.929 (1.19 to 0.666) 0.000**
AQL-5D (utility) 69 0.589 ± 0.126 0.687 ± 0.174 0.099 (0.134 to 0.063) 0.000**
TTO (utility) 87 0.650 ± 0.278 0.820 ± 0.264 0.170 (0.243 to 0.097) 0.000**
Wilcoxon signed-rank test
**p-value < 0.01 therefore statistically significant at the 1% level
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for improvements in asthma control. Previously, it has
been suggested that willingness to trade maybe associ-
ated with participant characteristics such as marital sta-
tus, age and family circumstances [37, 38]. Here
improvements (which largely occurred by week 4) may
also explain why participants were less likely to trade
any life years at weeks 4 and 8.
A particular application of this work is that the
estimated QALY loss can be used to enable other studies
[7, 39], which have estimated outcomes in terms of
asthma-related hospital admissions/crisis events, to con-
vert their results into a QALY score. With associated
cost data, this will enable the cost per QALY gain to be
estimated, and after taking account of guidance about
value for money [40], recommendations about provision
can be made, where this would not have otherwise been
possible. Also, as outlined in the introduction, re-
searchers and policy makers should be mindful that the
above described method, which is akin to mapping [12],
has the potential to produce different results to those
based on QALY values derived from follow-up at fixed
time points with linear interpolation. Comparison of
these two methods therefore represents a potential
avenue for further research.
Conclusion
To conclude, this study estimated the utility loss associ-
ated with asthma-related crisis events, where most of
the loss was observed within the first four weeks. The
EQ-5D-5 L, AQL-5D and TTO showed mean utility
changes between baseline and week 8 of 0.086, 0.154
and 0.132 respectively (p < 0.01). In turn, these values
can facilitate the estimation of cost-effectiveness, where
estimates of the associated QALY loss are combined
with data on the number of asthma-related crisis events.
Additional files
Additional file 1: Flow chart of study design. (PDF 248 kb)
Additional file 2: Mean changes in utility and score values between
week 4 and week 8 (available case analysis). (PDF 151 kb)
Additional file 3: Mean peak expiratory flow at daily time points.
(PDF 164 kb)
Additional file 4: Mean scores for difficulties sleeping, symptoms and
activities at daily points. (PDF 165 kb)
Additional file 5: Week 4 statistics for each quality of life questionnaire.
(PDF 151 kb)
Additional file 6: Week 8 statistics for each quality of life questionnaire.
(PDF 151 kb)
Abbreviations
A&E: Accident and emergency; AQL-5D: Asthma Quality of Life Utility Index-5
Dimensions; AQLQ: Asthma Quality of Life Questionnaire;
CLAHRC: Collaboration for Leadership in Applied Health Research & Care; EQ-
5D-3 L: EuroQol-5 Dimensions – 3Level; EQ-5D-5 L: EuroQol-5 Dimensions-5
Level; GP: General Practitioner; NHS: National Health Service; NICE: The
National Institute for Health and Care Excellence; NIHR: National Institute for
Health Research; PEF: Peak Expiatory Flow; PROMs: Patient reported outcome
measures; QALY: Quality Adjusted Life Year; RCP: Royal College of Physicians;
TTO: Time trade-off; UK: United Kingdom; VAS: Visual analogue scale
Acknowledgments
We would like to thank the participants who took part in this research, and
the respiratory research staff; Sarah Harper (Norfolk and Norwich University
Hospital), Dr. Benjamin Sutton (Queen Elizabeth Hospital, Birmingham),
Professor Graham Devereux, Victoria Fraser and Alison McKay (Aberdeen
Royal Infirmary) and Amy Dymond (York Health Economics Consortium).
Funding
This paper presents independent research funded by the National Institute
for Health Research (NIHR) Collaboration for Leadership in Applied Health
Research & Care (CLAHRC) East of England, at Cambridgeshire and
Peterborough NHS Foundation Trust. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the Department
of Health and Social Care.
Availability of data and materials
Participants provided written informed consent on the basis that this
research data was intended for use in a PhD with individuals from the
University of East Anglia, regulatory authorities and NHS trust being able to
access the data. The data reported in this paper can be used in other
ethically approved asthma studies.
Authors’ contributions
CJCB, TS, AW and GB were involved in the design of the study from
conception. CJCB was involved in recruitment, consent, follow up, data
collection and analysis of the participants in the study. CJCB drafted the
manuscript, with all authors providing critical revisions and final approvals.
Ethics approval and consent to participate
Approval was granted by the Cambridge South Research Ethics Committee
(REC reference: 16/EE0023). Written informed consent was provided by all
participants.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 17 August 2018 Accepted: 2 April 2019
References
1. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British
guideline on the management of asthma: A national clinical guideline 2016.
2. Asthma UK. Asthma facts and FAQs 2014 [19 February 2015]. Available from:
http://www.asthma.org.uk/asthma-facts-and-statistics.
3. Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M,
Fitzsimmons D, Bandyopadhyay A, Aftab C, Simpson CR, Lyons RA,
Fischbacher C, Dibben C, Shields MD, Phillips CJ, Strachan DP, Davies GA,
McKinstry B, Sheikh A. The epidemiology, healthcare and societal burden
and costs of asthma in the UK and its member nations: analyses of
standalone and linked national databases. BMC Med. 2016;14(1):113.
4. Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T,
Hahn RM, Schatz M. Asthma that is not well-controlled is associated with
increased healthcare utilization and decreased quality of life. J Asthma.
2011;48(2):126–32.
5. Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, Pertega-Diaz S, Verea-
Hernando H. Utility of brief questionnaires of health-related quality of life
(airways questionnaire 20 and clinical COPD questionnaire) to predict
exacerbations in patients with asthma and COPD. Health Qual Life
Outcomes. 2013;11:85.
Crossman-Barnes et al. Health and Quality of Life Outcomes           (2019) 17:58 Page 8 of 9
6. Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A.
Impact of asthma exacerbations and asthma triggers on asthma-related
quality of life in patients with severe or difficult-to-treat asthma. J Allergy
Clin Immunol Pract. 2014;2(5):544–52 e1–2.
7. Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-
effectiveness of a nurse-led telemonitoring intervention based on peak
expiratory flow measurements in asthmatics: results of a randomised
controlled trial. Cost Eff Resour Alloc. 2007;5:10.
8. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams
HC. Prophylactic antibiotics to prevent cellulitis of the leg: economic
analysis of the PATCH I & II trials. PLoS One. 2014;9(2):e82694.
9. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following
cervical cancer screening: event duration and health utility loss. Med Decis
Making. 2007;27(4):414–22.
10. Jakovljević MB, Tetsuji Y, Chia Ching C, Stevanovic DS, Jovanovic MR, Nikić
Djuričić KD, Rančić NK, Savić DM, Biorac NM, Mihajlovic GS, Jankovic SM.
Cost-effectiveness of depressive episode pharmacological treatment.
Hospital Pharmacology. 2015;2(1):235–45.
11. Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies
mapping from quality of life or clinical measures to EQ-5D: an online
database and application of the MAPS statement. Health Qual Life
Outcomes. 2018;16(1):31.
12. Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or
cross walking) non-preference based measures of health to generic
preference-based measures. Eur J Health Econ. 2010;11(2):215–25.
13. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in
NICE health technology assessments. Value Health. 2013;16(1):202–10.
14. Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A.
Preferred reporting items for studies mapping onto preference-based outcome
measures: the MAPS statement. Health Qual Life Outcomes. 2015;13:106.
15. Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of
participants. J Clin Nurs. 2010;19(1–2):227–33.
16. Perez DJ, McGee R, Campbell AV, Christensen EA, Williams S. A comparison
of time trade-off and quality of life measures in patients with advanced
cancer. Qual Life Res. 1997;6(2):133–8.
17. Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A,
Thomson R, Paleri V, Wilson JA. Quality compared to quantity of life in
laryngeal cancer: a time trade-off study. Head & neck. 2015;38(S1):631–37.
18. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The
“utility” of the time trade-off method in cancer patients: feasibility and
proportional trade-off. J Clin Epidemiol. 1995;48(10):1207–14.
19. van Reenen M, Janssen B. EQ-5D-5L user guide: basic information on how
to use the EQ-5D-5L instrument; 2015.
20. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation
of impairment of health related quality of life in asthma: development of a
questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.
21. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results
from a general population study. Health Econ. 1996;5(2):141–54.
22. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW.
Methods for the economic evaluation of health care Programmes. 4th ed.
New York: Oxford University Press; 2015.
23. NICE. Position statement on use of the EQ-5D-5L valuation set for England
(updated November 2018) 2018. Available from: https://www.nice.org.uk/
about/what-we-do/our-programmes/nice-guidance/technology-appraisal-
guidance/eq-5d-5l.
24. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia
X. Development and preliminary testing of the new five-level version of EQ-
5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
25. Devlin N, Shah K, Feng Y, Brendan M, van Hout B. Valuing health-related
quality of life: an EQ-5D-5L value set for England: research paper 16/01.
London: Office of Health Economics; 2016.
26. Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of rasch analysis in reducing
a large condition-specific instrument for preference valuation: the case of
moving from AQLQ to AQL-5D. Med Decis Making. 2011;31(1):195–210.
27. Shah K, Mulhern B, Longworth L, Janssen MF. An empirical study of two
alternative comparators for use in time trade-off studies. Value Health. 2016;
19(1):53–9.
28. Office for National Statistics. National life tables, United Kingdom: 2011–
2013 2017. Available from: https://www.ons.gov.uk/
peoplepopulationandcommunity/birthsdeathsandmarriages/
lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2014-09-25.
29. Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M. Control of
asthma in real life: still a valuable goal? Eur Respir Rev. 2015;24(136):361–9.
30. Pearson MG, Bucknall CE. Measuring clinical outcome in asthma: a patient-
focused approach. London: Royal College of Physicians; 1999.
31. Clement Clarke International. Personal predicted PEF 2004 [03 06 2017].
Available from: http://www.peakflow.com/top_nav/normal_values/
PEFNorms.html.
32. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-
related quality of life in moderate to severe asthma patients in the UK. Prim
Care Respir J. 2007;16(1):22–7.
33. Sturdy PM, Butland BK, Anderson HR, Ayres JG, Bland JM, Harrison BD,
Peckitt C, Victor CR. National Asthma Campaign M, severe morbidity G.
Deaths certified as asthma and use of medical services: a national case-
control study. Thorax. 2005;60(11):909–15.
34. Attema AE, Brouwer WB. The value of correcting values: influence and
importance of correcting TTO scores for time preference. Value Health.
2010;13(8):879–84.
35. Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations.
PharmacoEconomics. 2018;36(7):745–58.
36. Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z,
Meads D, O'Dwyer J, Barton G, Irvine L. EQ-5D-5L versus EQ-5D-3L: the
impact on cost effectiveness in the United Kingdom. Value Health. 2018;
21(1):49–56.
37. Sayah FA, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie
F, Johnson JA. Determinants of time trade-off valuations for EQ-5D-5L
health states: data from the Canadian EQ-5D-5L valuation study. Qual Life
Res. 2016;25(7):1679–85.
38. Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis:
time out for time tradeoff. Med Humanit. 2003;29(2):81–6.
39. Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, Windley J,
Holland R, Harrison BD, Howe A, Price DB, Harvey I, Wilson AM. The at-risk
registers in severe asthma (ARRISA) study: a cluster-randomised controlled
trial examining effectiveness and costs in primary care. Thorax. 2012;67(12):
1052–60.
40. NICE. Guide to the methods of technology appraisal. 2013:2013.
Crossman-Barnes et al. Health and Quality of Life Outcomes           (2019) 17:58 Page 9 of 9
